Autoinflammatory Disease
Conditions
Brief summary
Auto-inflammatory diseases are part of a heterogeneous group of illnesses manifested by an inflammatory reaction in its initial phase (innate immunity) that is activated inappropriately: either because the reaction is too strong, or because it is not justified (e.g. in the absence of infection). Autoinflammatory diseases are often initially described as genetic in origin (i.e. hereditary or familial), and preferentially affect children or young adults. However, the preponderance of auto-inflammation as a cause of symptoms has led to the development of a number of other diseases. In some cases, autoinflammatory diseases may also remain unclassified. Generally speaking, autoinflammatory diseases manifest as recurrent attacks of fever, rash and joint pain. Certain signs are more specific to certain diseases, such as urticaria, abdominal pain, mouth ulcers or cervical lymph nodes... It is above all the repetition of the attacks and their unprovoked nature that attract the attention of the patient and the doctor. These attacks are systematically associated with an increase in inflammation markers in the blood. At present, not all inflammation pathways have been identified. With this study, investigator aim to characterize rare autoinflammatory disease variants and develop relevant cellular models to study inflammation pathways.
Interventions
blood test as part of routine care
Sponsors
Study design
Eligibility
Inclusion criteria
For adults : Inclusion Criteria : * Major patient * Patient with a rare autoinflammatory disease * Patient who has given his or her consent to participate in research
Exclusion criteria
: * Patient under legal protection or safeguard of justice or any other protective measure (guardianship, curatorship) * Patient with known infection with hepatitis B or C virus or human immunodeficiency virus (HIV) For Kids : Inclusion Criteria : * Minor patients (between 4 and 17 years of age) * Patient with a rare autoinflammatory disease. * No additional genetic research will be carried out as part of the project. * Parents/legal guardians of the child who have given their non-objection to participate in the research.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The main judgment criterion will be analysis of the Cytokine/chemokine release assays. | At inclusion Day 0 | Comparison of pro- and anti-inflammatory cytokine concentrations (IL-8, TNF (Tumor Necrosis Factor), chemokine CC ligand 3 and 4 concentrations (CCL3, CCL4) by ELISA in cells supernatants according to the inflammatory pathway involved. |